

Meeting Date	12 November 2024	Agenda Item	
Report Title	Infection Prevention and Control Report		
Report Author	Joanne Walters, Deputy Head of Nursing Infection Prevention & Control		
Report Sponsor	Hazel Powell, Executive Director of Nursing & Patient Experience.		
Presented by	Delyth Davies, Head of Nursing Infection Prevention & Control.		
Freedom of Information	Open		
Purpose of the Report	This report provides the Quality & Safety Governance Group members with the Infection Prevention & Control position paper to the end of Q2 as presented to the Infection Prevention & Control Strategic Group (IPCSG) meeting held on the 29 th October 2024.		
Key Issues	<p>Key items for escalation to the Quality & Safety Committee from the IPCSG meeting October 29th 2024 include:</p> <ul style="list-style-type: none"> • <i>C. difficile</i> cases continue to increase. The number of cases in August 2024 was the highest seen in the health board, with the highest proportion being hospital-onset cases. A Gold <i>C. difficile</i> High Incidence Management Group was established in response. • Hospital onset case numbers for the four infections exceeded the Targeted Intervention de-escalation criteria during the quarter. • Covid-19 and Norovirus incidents during Quarter 2 across all hospital sites led to temporary bed closures and compounded existing service pressures and demand for single rooms. • Incidents relating to Pneumocystis pneumonia, Measles and Creutzfeldt-Jakob disease (CJD) occurred within the health board during Quarter 2. Lessons for learning were identified. • The health board continues to face significant challenges relating to healthcare associated infection risks, which are recorded in the health board's Risk Register. 		
Specific Action Required (please choose one only)	Information	Discussion	Assurance
	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Recommendations	Members are asked to:		

	<ul style="list-style-type: none">• NOTE: the health board’s Quarter 2 position in relation healthcare associated infections.• NOTE: the exceptional number of <i>C. difficile</i> cases seen in August 2024, and the establishment of the Gold <i>C. difficile</i> High Incidence Management Group.• NOTE: the performance of the health board to Targeted Intervention for performance in relation to HCAs.• NOTE: progress on Infection Prevention & Control Improvement Plan to 30th September 2024.• NOTE: the improvement in IPC Level 2 training to 82.19% compliance reported at 30th September 2024.• NOTE: the challenges and risks within the health board currently and associated mitigations.
--	--